anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Written and verbal consents are obtained by informing the mothers about the study, and the information about the preterm infants and their mothers is recorded. Preterm infants, whose transition to oral feeding was decided by the physician and nurse and whose families gave consent to participate in the study, were randomly assigned to 2 groups as experimental (supplemental feeding system; SFS) and control (bottle feeding group; BFG). After oral feeding is decided, the first feeding of preterm infants in both groups is tried directly on the mother's breast and the early feeding skill score is 57, with heart rate (120-160/min), sPO2(\>90) and respiratory rates (40-60/min) during the time they are at the mother's breast. min) are not included in the study, whose follow-ups are between normal values. The first feeding of the infants in both groups is carried out between 08:00 and 16:00 and the body weights of the infants are measured daily with the same scale before feeding.The amount in which the food (breast milk) is prepared to be given orally to the baby is recorded. The feeding time of all infants was limited to a maximum of 30 minutes. The feeding time of the infants are recorded in the feeding follow-up form. Before, during and after feeding, the heart rate, SPO2 and respiratory rates of the infants are recorded by pulse oximetry. During feeding, infants are evaluated with their early feeding skills by an observing nurse and their scores are recorded. Physiological parameters of infants are recorded before, during and after feeding is started, infants who are desaturated (SPO2 below 90%) during feeding are rested and feeding is continued after their saturation rises above 90% and these rest periods are also included in the feeding. After the decision to switch to oral feeding, the infants in the experimental group are fed 3 meals a day with the supplemental feeding system (daytime feedings), other meals are carried out with a bottle, and all the feedings of the infants in the control group are carried out with a bottle, which is the service routine. Infants' nutritional skills are evaluated at each meal, and their physiological measurements are recorded. After the evaluations of the infants who could not take the whole recommended amount of food in both groups (feeding time, recommended amount of food, amount of food the infant took, early feeding skill score and physiological parameters were recorded, the nurse completes the feeding of the infant with a bottle. The infants are followed up between 8-16 hours. The evaluations made at 3 meals are recorded. Infants who are fed orally for 8 meals a day for two consecutive days, and who can take 80% of the amount of food given at each meal, are considered to have switched to full oral feeding and the follow-up of the ınfants are stopped. The study followed the CONSORT guideline for reporting randomized controlled trials.
24 adolescents and young adults between the ages of 12 and 25 who are at high risk of developing psychosis and exhibit paranoid ideation will be recruited to participate in a pilot randomized controlled trial. Subjects will be randomly assigned to the intervention (GF-CBT)or control (symptom monitoring) groups. GF-CBT is based on a cognitive neuropsychiatric model of delusions, and incorporates recent developments in learning and cognitive theories. GF-CBT consists of individual, group, and family group sessions. The three-part program teaches adolescents and family members Cognitive Behavioral skills that they can continue using on their own after completion of the program. Preliminary efficacy of the intervention will be evaluated using standardized measures by blind evaluators conducted at baseline, post-treatment, and post-termination follow-up over the next 2 years. Hypotheses: (a) GF-CBT will be associated with: high rate of remission from "at risk status" and low rates of transition to psychosis (defined by CAARMS criteria); greater improvements in severity of symptoms; and improved functioning; (b) decrease in family members'level of stress, and improved coping; (c) Family members will demonstrate proficiency in CBT Skills.
Early life Western diet (WD) consumption leads to impaired memory function, particularly for processes mediated by the hippocampus. However, the precise critical developmental window(s) during which WD exposure negatively impacts hippocampal function are unknown. Here, we exposed male and female rats to a WD model involving free access to a variety of high-fat and/or high-sugar food and drink items during either the early-adolescent period (postnatal days [PN] 26-41; WD-EA) or late-adolescent period (PN 41-56; WD-LA). Control (CTL) rats were given healthy standard chow throughout both periods. To evaluate long-lasting memory capacity well beyond the early life WD exposure periods, we performed behavioral assessments after both a short (4 weeks for WD-EA, 2 weeks for WD-LA) and long (12 weeks for WD-EA, 10 weeks for WD-LA) period of healthy diet intervention. Results revealed no differences in body weight or body composition between diet groups, regardless of sex. Following the shorter period of healthy diet intervention, both male and female WD-EA and WD-LA rats showed deficits in hippocampal-dependent memory compared to CTL rats. Following the longer healthy diet intervention period, memory impairments persisted in male WD-EA but not WD-LA rats. In contrast, in female rats the longer healthy diet intervention reversed the initial memory impairments in both WD-EA and WD-LA rats. Collectively, these findings reveal that early-adolescence is a critical period of long-lasting hippocampal vulnerability to dietary insults in male but not female rats, thus highlighting developmental- and sex-specific effects mediating the relationship between the early life nutritional environment and long-term cognitive health.
First，30 pregnant women with GDM and 60 pregnant control women with normal glucose tolerance (NGT) matched for maternal and gestational age were enrolled in the study. All the subjects underwent antepartum screening in the First Affiliated Hospital of Sun Yat-sen University. Blood samples were obtained after overnight fasting at the time of oral glucose tolerance test (OGTT). Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.

Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed.

Data were analyzed by SPSS 20.0 database. The results were expressed as mean ± standard deviations or median with interquartile range. Differences between groups were assessed by Student's unpaired t test, Mann-Whitney U test, or Chi-square test as appropriate. Correlation analysis was performed using the Spearman rank correlation method. To identify independent relationships and adjust the effects of covariates, multiple linear regression analyses were performed. P values of \<0.05 were considered significant.
An exercise apparatus includes a motor, an operating member driven by the motor, a sensor operable to detect engagement of a user with the operating member, and a controller in communication with the operating member and the sensor. The controller is configured to generate exercise use data when the operating member is driven by the motor. A communication interface is in communication with the controller. In response to the controller determining that the user is engaged with the operating member, the controller is configured to report the exercise use data to the communication interface. In response to the controller determining that the user is not engaged with the operating member, the controller is configured to stop reporting the exercise use data to the communication interface. The communication interface is configured to communicate the reported exercise use data to a third party.
First, patients with prostate cancer will be included during step 1. They will have an interview.
BACKGROUND: This study investigates the relationship between triglyceride-glucose (TyG) index trajectories and the results of ablation in patients with stage 3D atrial fibrillation (AF).
METHODS: A retrospective cohort study was carried out on patients who underwent AF Radiofrequency Catheter Ablation (RFCA) at the Cardiology Department of the Fourth Affiliated Hospital of Zhejiang University and Taizhou Hospital of Zhejiang Province from January 2016 to December 2022. The main clinical endpoint was determined as the occurrence of atrial arrhythmia for at least 30 s following a 3-month period after ablation. Using a latent class trajectory model, different trajectory groups were identified based on TyG levels. The relationship between TyG trajectory and the outcome of AF recurrence in patients was assessed through Kaplan-Meier survival curve analysis and multivariable Cox proportional hazards regression model.
RESULTS: The study included 997 participants, with an average age of 63.21 ± 9.84 years, of whom 630 were males (63.19%). The mean follow-up period for the participants was 30.43 ± 17.75 months, during which 200 individuals experienced AF recurrence. Utilizing the minimum Bayesian Information Criterion (BIC) and the maximum Entropy principle, TyG levels post-AF RFCA were divided into three groups: Locus 1 low-low group (n = 791), Locus 2 low-high-low group (n = 14), and Locus 3 high-high group (n = 192). Significant differences in survival rates among the different trajectories were observed through the Kaplan-Meier curve (P < 0.001). Multivariate Cox regression analysis showed a significant association between baseline TyG level and AF recurrence outcomes (HR = 1.255, 95% CI: 1.087-1.448). Patients with TyG levels above 9.37 had a higher risk of adverse outcomes compared to those with levels below 8.67 (HR = 2.056, 95% CI: 1.335-3.166). Furthermore, individuals in Locus 3 had a higher incidence of outcomes compared to those in Locus 1 (HR = 1.580, 95% CI: 1.146-2).
CONCLUSION: The TyG trajectories in patients with stage 3D AF are significantly linked to the outcomes of AF recurrence. Continuous monitoring of TyG levels during follow-up may help in identifying patients at high risk of AF recurrence, enabling the early application of effective interventions.
A method of preventing underarm malodor associated with human perspiration. There is applied to the skin of a human, a safe and effective amount of a macroporous crosslinked copolymer containing acrylate or methacrylate units. Components of sweat such as fatty acids found in human perspiration, are adsorbed and entrapped into and within the confines of the macroporous copolymer. The macroporous copolymer possesses a pore diameter of a size sufficiently small to inhibit skin bacteria from entering. Decomposition of fatty acid and sweat components by the skin bacteria is thereby retarded, and hence the generation of body malodor is reduced. The macroporous copolymer may be applied to the human skin in the form of a deodorant stick, a deodorant cream, a deodorant lotion, a deodorant spray, a deodorant roll-on, a deodorant pad, a pressed powder deodorant, a loose powder deodorant or a deodorant gel.
Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
The invention provides an externally-applied medicine for treating pain. The externally-applied medicine is prepared by taking the following traditional Chinese medicines in parts by weight as raw materials: 5-6 parts of ligusticum wallichii, 3-8 parts of notopterygium root, 1-5 parts of radix angelicae, 2-4 parts of cattail pollen, 1-4 parts of elecampane, 2-4 parts of pseudo-ginseng, 1-4 parts of clove, 1-2 parts of rheum officinale, 1-3 parts of amber, 2-4 parts of radix clematidis, 10-20 parts of radix angelicae pubescentis, 2-5 parts of garden balsam stem, 2-5 parts of corydalis tuber, 1-2 parts of parasitic loranthus, 0.5-2 parts of borneol and 2-5 parts of liquorice. The preparation method of the externally-applied medicine comprises the following steps: respectively processing, preparing and crushing the traditional Chinese medicines, mixing the traditional Chinese medicines, filling the mixture into a cloth bag sewn with a band, and sealing the bag opening, thereby obtaining a finished product. The medicine bag is fixed by the band during use, so that the medicine bag is bound and attached to the pain location. One medicine bag can be continuously used for 20 days and can be used for 8-16 hours per day. The externally-applied medicine disclosed by the invention can be used for alleviating the pain to moderate pain and is high in curative effect and fast in effectiveness, and the total effective rate is 97.8 percent.
The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
A pharmaceutical composition consisting of a first pharmaceutically active portion consisting of one or more cannabinoids; a second pharmaceutically active portion consisting of one or more of glutathione, cysteine, acetylcysteine, alliin, bucillamine, carbocysteine, djenkolic acid, felinine, lanthionine, mecysteine hydrochloride, penicillamine cysteine disulphide, or any functional equivalent thereof; and optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active portion to the first pharmaceutically active portion is at least 0.5:1. Preferably, the first pharmaceutically active portion consists of cannabidiol, cannabinol, tetrahydrocannabinol or a mix thereof. Preferably, the second pharmaceutically active portion consists of glutathione. Also claimed is a method of manufacturing the pharmaceutical composition from cannabis plant material, comprising the steps of extracting a first fraction containing one or more cannabinoids from the cannabis plant material using a polar solvent; extracting a second fraction containing glutathione from the same cannabis plant material using water; and drying and combining the first fraction and the second fraction to form the pharmaceutical composition. Preferably, the polar solvent is ethanol. The cannabis plant material may consist of dried cannabis plant. The pharmaceutical composition of the invention aims to negate the hepatotoxic effect of isolated cannabinoids.
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
NEW MATERIAL:The compound of formula I (R<1>-R<7> are lower alkyl) or its pharmacologically allowable salt. EXAMPLE:1-(3, 4-Dimethoxyphenyl)-2, 3-bis(methoxycarbonyl)-4-hydro-xy-6, 7, 8-trimethoxynaphthalene. USE:A drug. A remedy for hyperlipemia. It suppresses the total cholesterol level in blood but increases HDL-cholesterol level. Preferable as a remedy and preventive for arteriosclerosis. It has high safety and can be administered without causing side effect such as hepatic function disorder (e.g. jecur adiposum) at the active dose. Dose: 5-35mg/kg-weight per day. PREPARATION:The objective compound of formula I can be produced by reacting an acetylene compound of formula II with a novel benzaldehyde compound of formula III, its di-lower alkyl acetal or its salt preferably in the presence of a solvent such as benzene and an acid catalyst such as p-toluenesulfonic acid.
The invention discloses an orthopedic intelligent treatment system and a using method thereof, and relates to the technical field of intelligent treatment. The intelligent treatment system for the orthopedics department comprises an appointment system, an intelligent processing terminal and a self-service treatment room, wherein the appointment system and the self-service treatment room are in communication connection with the intelligent processing terminal. The reservation system is used for acquiring personal information and disease information of orthopedic patients and transmitting the personal information and the disease information to the intelligent processing terminal. The intelligent processing terminal is used for obtaining a treatment prescription according to the disease information and transmitting the treatment prescription and the personal information to the self-service treatment room. The self-service treatment room is used for treating the orthopedic patients according to the treatment prescription. The invention also provides a using method of the intelligent treatment system for the orthopedics department. The orthopedic intelligent treatment system and the use method thereof provided by the invention have the characteristic of convenience in use, can realize intelligent orthopedic treatment, and are greatly convenient for orthopedic patients to seek medical treatment.
The present invention discloses a pharmaceutical composition of fibrinogen particles suitable for intravenous injection. The composition comprises a combination of human albumin and fibrinogen. The human albumin is made into a human albumin suspension according to a specific method, which is then cross-linked with fibrinogen. The composition particle will not coagulate in a suspension and has a diameter smaller than 1 micron-meter. The protein particle composition, through intravenous injection, will not cause a blockage in the blood vessel. However, it will promote the blood coagulation of a wound, and can effectively reduce the loss of blood of a patient.
The safety and effectiveness of bevacizumab products in pediatric patients have not been established. In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years who received bevacizumab. Bevacizumab products are not approved for use in patients under the age of 18 years.

Antitumor activity was not observed among eight pediatric patients with relapsed GBM who received bevacizumab and irinotecan. Addition of bevacizumab to standard of care did not result in improved event-free survival in pediatric patients enrolled in two randomized clinical studies, one in high grade glioma (n=121) and one in metastatic rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma (n=154).

Based on the population pharmacokinetics analysis of data from 152 pediatric and young adult patients with cancer (7 months to 21 years of age), bevacizumab clearance normalized by body weight in pediatrics was comparable to that in adults.

Juvenile Animal Toxicity Data

Juvenile cynomolgus monkeys with open growth plates exhibited physeal dysplasia following 4 to 26 weeks exposure at 0.4 to 20 times the recommended human dose (based on mg/kg and exposure). The incidence and severity of physeal dysplasia were dose-related and were partially reversible upon cessation of treatment.
Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
The invention relates to the chemical-and-pharmaceutical industry, in particular technology of manufacturing the aerosol drug formulation, and may be used for manufacturing the topical drug irritating nerve terminations. The method comprises mixing the drug substance, Tween-80 as a stabilizer, ethanol, glycerol, and the purified water followed by filling the aerosolic balloons. The active substance represents 25% solution of menthol in menthyl ester of isovalerianic acid. First, the Tween-80 is mixed with 96% ethanol. Then 25% solution of menthol in menthyl ester of isovalerianic acid is added to the mixture. Finally, the mixture is added by portions to the water, and the final composition is emulsified.
INTRODUCTION: Several studies have shown the positive effect on weight loss of the banded Roux-en-Y gastric bypass (BRYGB). Thus far, studies describing the 10-year post-operative results are scarce. Therefore, the aim of this study was to describe the weight loss results, effect on associated medical problems, and complication rates during 10 years of follow-up after BRYGB.
METHOD: Data were collected from patients who underwent laparoscopic BRYGB with a non-adjustable silicone gastric ring between January 2011 and March 2013. All patients were included when found to be eligible according to the IFSO criteria.
RESULTS: One hundred forty-nine patients were included, 110 received a primary BRYGB and 39 received a conversional BRYGB. The primary BRYGB group consisted of 68% female patients with a mean BMI of 44.5 kg/m2 and a mean age of 46 years old. The conversional group consisted of 77% females and had a mean BMI of 34.8 kg/m2 and a mean age of 48 years. At 10-year follow-up, 67.1% of the data was available. Ten-year post-operative 30% total weight loss was seen in the primary group, and 7% in the conversional group. In 10 years, 23% of the patients had complications of which half were ring-related.
CONCLUSION: The addition of a silicon ring to the Roux-en-Y gastric bypass may result in substantial and stable weight loss maintenance 10 years post-operative. Furthermore, the number of patients with long-term complications was low and the number of associated medical problems was significantly reduced.
This is a 13-wk double-blinded, randomized, crossover study design. Following a 1-wk pre-intervention baseline period, subjects will be randomly assigned to follow a healthy eating pattern diet either contain 2.0 g free plant sterols equivalent of their palmityl esters (Plant Sterol Diet) or do not contain plant sterols (Control Diet) for 4 weeks. After a 4-week dietary 'washout' period, they will consume the alternative diet for 4 weeks. The random assignment will be done with SAS 9.4 software. Body size measurement, dietary assessment, brachial artery FMD and blood pressure measurements, and fasting-state blood collection will be conducted at week 1, 5, 9, and 13, which correspond to before and during the last 1 week of the two 4-week intervention periods.

During study week 1 and weeks 6-9, all subjects will consume their habitual, unrestricted self-chosen diets. During study weeks 2-5 and 10-13, all subject will follow a healthy eating pattern diet, referred to as the "My Healthy Plate" designed by HPB. Each subject's energy requirement will be estimated using sex-specific equations and Recommended Dietary Allowances for healthy Singaporean. One-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff to achieve a healthy eating pattern diet. Compliance with the plant sterols consumption will be promoted by frequent online and in-person contact.